アフィニトール｜製品情報｜医療関係者向け｜ノバルティス ファーマ DR's Net
WEB製品基本情報、疾患別（乳がん、神経内分泌腫瘍、結節性硬化症）の製品情報、患者さま向け提供情報・資料をご紹介しています。
Three new Novartis medicines approved in Japan for ... - Fierce …
WEBJan 20, 2010 · Afinitor (everolimus) in tablet form has been approved in Japan for the treatment of patients with non-resectable, metastatic renal cell carcinoma (advanced kidney cancer).
RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis
WEBJul 16, 2008 · In January 2010, Novartis announced that Afinitor was approved in Japan for treating people affected with non-resectable, metastatic renal cell cancer.
Novartis drug Afinitor DISPERZ® receives FDA approval to treat …
WEBApr 10, 2018 · Afinitor DISPERZ is the first adjunctive treatment approved in the US specifically for adult and pediatric patients aged 2 years and older with tuberous sclerosis complex (TSC)-associated...
Novartis Drug Afinitor® Effective in Patients With Non-Cancerous …
WEBSep 23, 2011 · In the US, Afinitor® (everolimus) tablets is approved to treat patients with SEGA associated with TS who require therapeutic intervention but are not candidates for curative surgical resection. The effectiveness of everolimus is based on an analysis of change in SEGA volume.
Everolimus - Wikipedia
WEBEverolimus, sold under the brand name Afinitor among others, is a medication used as an immunosuppressant to prevent rejection of organ transplants [10] and as a targeted therapy in the treatment of renal cell cancer and other tumours.
Novartis joins Eisai to push Lenvima and Afinitor combo in U.S.
WEBJun 3, 2016 · The Swiss drugmaker, which faces its own challenges, will promote Lenvima in combination with its own Afinitor (everolimus). The partnership comes after the FDA last month approved the combo to...
Novartis gets Japan's approval for three drugs | Reuters
WEBJan 20, 2010 · Afinitor in tablet form has been approved in Japan for the treatment of patients with non-resectable, metastatic renal cell carcinoma (advanced kidney cancer), …
WEBAfinitor is indicated for the treatment of: • Hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after
Everolimus (Afinitor) | FDA - U.S. Food and Drug Administration
WEBOn February 26, 2016, the U. S. Food and Drug Administration approved everolimus (Afinitor , Novartis) for the treatment of adult patients with progressive, well-differentiated non-functional,...